INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Under the Paperwork Reduction Act of 1995, no persons are req

Application Number		10805644
Filing Date		2004-03-19
First Named Inventor Vinor		Winstead
Art Unit		
Examiner Name		
Attorney Docket Number		81099039

				U.S.	PATENTS	Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	4129040		1978-12-12	Hayden, Jr.			
	2	4794891		1989-01-03	Knobloch			
	3	5072702		1991-12-17	Sasaki et al.			
	4	5921216		1999-07-13	Bailman et al.			
	5	6269632		2001-08-07	Schmitz			
	6	6321700		2001-11-27	Hein et al.			
	7	6446588		2002-09-10	Yamada et al.			
	8	6975935		2005-12-13	Kohler et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10805644
Filing Date		2004-03-19
First Named Inventor Vince		Winstead
Art Unit		
Examiner Name		
Attorney Docket Number		81099039

	Cite No	Publication	Number	Kind Code ¹		tion	Name of Bat			Columns,Lines when	
	1						Name of Patentee or Applicant		Pages,Columns,Lines who Relevant Passages or Rel Figures Appear		
		2001005006	65		2001-12-13 Yamada et a						
:	2	2005019922	20		2005-0	9-15	Ogiso				
If you wish	to ad	d additional	U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d buttor	n. Add	
					FOREIG	3N PAT	ENT DOCUM	ENTS		Remove	
Examiner (Cite No	Poreign Document Country Kind Publication Applic		Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	T4				
	1										
If you wish	to ad	d additional	Foreign Pa	atent Do	cument	citation	information pl	ease click the Add	button	Add	_
				NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (look, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							Τs				
	1										
If you wish	to ad	d additional	non-paten	t literatu	re docu	ment cit	tation informat	on please click the	Add b	utton Add	_
					EX	AMINE	R SIGNATUR	E			_
Examiner S	Signa	ture						Date Consid	ered		_
								ormance with MPE with next communi		Draw line through a p applicant.	

	Application Number		10805644
INFORMATION DIGGI COURT	Filing Date		2004-03-19
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Vince		Winstead
	Art Unit		
	Examiner Name		
	Attorney Docket Number	er	81099039

See for Codes of USPTO Patient Documents at your USPTO, CODE on MEPP 901.04. * Exister office in all research on documents, by the loss before code (WPO) Standard 51.3. * *Projectioned person of the patient obscurred. The patient obscurred is because the search received the patient obscurred. * More of document by the appropriate symbols as indicated on the document with the patient obscurred. * More of document by the appropriate symbols as indicated on the document under WPO Standard 51.56 if possible. * Applicant is to place a check mark here if Exploit language the search can see a support of the patient obscurred.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Art Unit

Application Number		10805644		
Filing Date		2004-03-19		
First Named Inventor Vince		Winstead		
Art Unit				
Examiner Name				
Attorney Docket Number		81099039		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/John D. Russell/	Date (YYYY-MM-DD)	2006-10-09
Name/Print	John D. Russell	Registration Number	47048

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandriu, V.S. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a pleath pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via stife of manaplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.